BG Medicine Inc. reported a wider net loss in the second quarter of $6.4 million the Waltham company cited higher costs and it withdrew an application to the Food and Drug Administration for approval for a diagnostic test. The company said it could not meet an Aug. 15 FDA deadline to supply more information about its CardioScore test but plans to resubmit the application for regulatory approval. CardioScore is its lead product candidate a blood test for atherothrombotic cardiovascular disease, commonly known as vulnerable plaque.

For more from BostonGlobe.com, sign up or log in below

Access the full articles and quality reporting of The Boston Globe at BostonGlobe.com

Unlimited Access to BostonGlobe.com for 4 weeks for only 99.

Get FREE access as part of your print subscription.

See the rest here:

BG Medicine’s net loss widens